Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
Interventions: BAY1213790 (Osocimab), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 704 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 26
States / cities: Azusa, California • Brawley, California • Encino, California + 21 more

Conditions: Cervical Cancer, Precancerous Condition
Interventions: imiquimod, Ablative or excisional therapy; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 8
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more

Conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
Interventions: ABBV-400, Trifluridine/Tipiracil, Bevacizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 18
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 13 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK1292263, GSK1292263 matching placebo, Sitagliptin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more

Conditions: Healthy Volunteers
Interventions: MLN3126, MLN3126 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Rebound Pain, Shoulder Arthroplasty, Interscalene Block
Interventions: Bupivacaine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Acute Myeloid Leukaemia (AML)
Interventions: Venetoclax, Decitabine/Cedaruridine, decitabine/cedazuridine; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Asthma
Interventions: Treatment A: Fp MDPI, Treatment B: FS MDPI, Treatment C Flovent, Treatment D: Advair; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 3
States / cities: Raleigh, North Carolina • Edmond, Oklahoma • San Antonio, Texas

Conditions: Melanoma, Neoplasm Metastasis
Interventions: gp100:209-217 (210M), Montanide ISA-51, IL-2, MART-1:26-35(27L), Abl cells, Fludarabine, Cyclophosphamide, GCSF (Growth colony stimulating factor), Apheresis; Drug · Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Suppression
Interventions: Low dose formulation, High dose formulation; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: PRA023 IV Low Dose, PRA023 SC, Placebo IV, Placebo SC, PRA023 IV High Dose; Drug
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Acute Myeloid Leukemia
Interventions: Quizartinib, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 1 Month to 21 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 11
States / cities: Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: COPD
Interventions: Low Dose Corticosteroids, High Dose Corticosteroids; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 40 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Plainsboro, New Jersey

Conditions: Hypopituitarism
Interventions: Human Growth Hormone (1-134), Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cognitive Impairment
Interventions: Single Dose of VU319, Single Dose Placebo, Fed State, Fasted State, Dose Escalation of VU319, Placebo Dose Escalation; Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Small Cell Carcinoma
Interventions: Abemaciclib,; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Stroke, Endovascular Thrombectomy
Interventions: Nicardipine, Labetalol, Hydralazine; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Hartford, Connecticut • Cincinnati, Ohio • Nashville, Tennessee

Conditions: Healthy
Interventions: Investigational Product - MIB 626, Placebo, Standardized, progressive, high intensity, multidimensional exercise, Usual Physical Activity; Drug · Other
Lead sponsor: Metro International Biotech, LLC; Industry
Eligibility: 19 Years to 40 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioma
Interventions: RTA 744, RTA 744 injection; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 4
States / cities: Los Angeles, California • Dallas, Texas • Houston, Texas

Conditions: Clonal Cytopenia of Undetermined Significance
Interventions: Ivosidenib; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 2
States / cities: St Louis, Missouri • Cleveland, Ohio

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Palovarotene, midazolam; Drug
Lead sponsor: Clementia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions: Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Tamoxifen Citrate, Trastuzumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 3,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 154
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more

Conditions: Norovirus Gastroenteritis
Interventions: VXA-G1.1-NN Oral Vaccine; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 19 Years to 49 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Influenza Immunization
Interventions: Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 28
States / cities: Chula Vista, California • Gardena, California • Long Beach, California + 24 more

Search by objective public record fields.

Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis

Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

MLN3126 Single Rising Dose Study

Effect of Local Anesthetic Concentration on Rebound Pain

Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Obesity, Oral Contraception, and Ovarian Suppression

Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Dose of Corticosteroids in COPD

Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency

Putative Cognitive Enhancer VU319

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Blood Pressure After Endovascular Stroke Therapy-II

Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older